Invesco China Small Cap ETF (HAO)

$HAO: 1 for 128 RS goes down Tomorrow ........

Now at $0.016

GO $HAO

***********************************************************************

https://ir.haoximedia.com/news-releases/news-release-details/haoxi-health-technology-limited-announces-1-128-reverse-share


Haoxi Health Technology Limited Announces 1-For-128 Reverse Share Split
By Haoxi Health Technology Limited | May 19, 2026, 8:30 AM

Share
HAO
-21.35%
Haoxi Health Technology Ltd
BEIJING, May 19, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (NASDAQ: HAO; “we” or the “Company”), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0025 per share (the “Class A Ordinary Shares”) and Class B ordinary shares, par value $0.0025 per share (the “Class B Ordinary Shares”), at a ratio of 1-for-128.

Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on May 21, 2026. Following the reverse share split, the Class A Ordinary Shares and Class B Ordinary Shares will have a new par value of $0.32 per share and the Class A Ordinary Shares will continue to trade on Nasdaq under the symbol “HAO” with the new CUSIP number, G4290F126. The reverse share split is expected to lead the Company’s Class A Ordinary Shares to trade at approximately 128 times the price per share at which it trades prior to the effectiveness of the reverse share split. The Company, however, cannot assure that the price of its Class A Ordinary Shares after the reverse split will reflect the 1-for-128 reverse split ratio, that the price per share following the effective time of the reverse split will be maintained for any period of time, or that the price will remain above the pre-split trading price.

No fractional shares will be issued in connection with the reverse share split and all such fractional interests will be rounded up to the nearest whole number of Class A Ordinary Shares and Class B Ordinary Shares.

The reverse share split will reduce the number of issued and outstanding Class A Ordinary Shares from 235,504,007 to approximately 1,839,876, and the number of issued and outstanding Class B Ordinary Shares from 690,800 to approximately 5,397, subject to any adjustments resulting from the treatment of the fractional shares.

On March 24, 2026, the board of directors of the Company approved the reverse share split of the Class A Ordinary Shares and Class B Ordinary Shares, at a ratio of 1-for-128.

Transhare Corporation LLC is acting as the exchange agent and paying agent for the reverse share split. Shareholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse share split.

Transhare Corporation LLC will provide instructions to any shareholders with certificates regarding the process in connection with the exchange of pre-reverse share split share certificates for ownership in book-entry form or share certificates on a post-reverse share split basis. Shareholders are encouraged to contact their bank, broker or custodian with any procedural questions.

About Haoxi Health Technology Limited

Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company’s growth is driven by the rise of news feed ads and the rapid development of the healthcare section. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, Wechat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers. For more information on our latest innovations and developments, visit http://ir.haoximedia.com.

$HAO: HOLLY CRAPpppp offering......................................

They just EZGO'ed this one too............... down to $0.042

Damnnnnnnnnn these chiners.


Now its on RS watch like EZGO last week..................... holy hell.

Every week its another CHINER doing this.


GO $HAO

$HAO: Haoxi HEALTH Tech......... waiting to RIPPppppppp

Price is actually $0.62

https://www.haoximedia.com/#page5

The next one to rip like $HCAI just did

GO $HAO

***************************************************************************


HAOXI HEALTH TECHNOLOGY and Eaglepoint AI Forge Strategic Partnership to Enter AI-Powered Health Management Track
By Haoxi Health Technology Limited | March 03, 2026, 7:30 AM

Share
HAO
-22.11%
Haoxi Health Technology Ltd
BEIJING, March 03, 2026 (GLOBE NEWSWIRE) -- HAOXI HEALTH TECHNOLOGY LIMITED (NASDAQ: HAO) (the “Haoxi Health”), a U.S. publicly listed company, and Eaglepoint AI Inc., a subsidiary of Global Mofy AI Limited (NASDAQ: GMM), today jointly announced the signing of a three-year strategic cooperation agreement. The two parties will jointly commit R&D, data, and channel resources to launch an AI health management platform in China. Haoxi Health believes that this partnership marks its's exploration of potential opportunities in the AI-enabled healthcare sector. This collaboration also represents the first time that Eaglepoint AI has deployed its Aquila data engine and multimodal model evaluation system in a high-growth health management scenario.

Under the agreement, both parties will explore collaboration in the AI-enabled preventive healthcare applications, including intelligent nutrition, chronic disease risk assessment, and digital therapeutics. HAOXI HEALTH plans to contribute its marketing networks to provide user reach and commercial conversion support, while Eaglepoint AI will be responsible for technical support in model training, data security compliance, and algorithm iteration. The first phase of the project will launch the "AI Digital Health Manager" SaaS system targeting sub-healthy and chronic disease populations.

Mr. Fan Zhen, CEO of Haoxi Health, stated: "The company has long served domestic and international healthcare clients, managing tens of billions of online advertising data points. We understand clients' urgent demand for personalized, quantifiable health management solutions. Eaglepoint AI possesses capabilities in data governance and multimodal model evaluation. Its proprietary Aquila platform has achieved automated comparative experiments with mainstream large models including Claude, GPT, and Gemini, improving model iteration efficiency by 3.5 times. We believe this collaboration will integrate HAOXI's marketing traffic advantages with Eaglepoint's algorithmic strengths."

Both parties believe that the collaboration between HAOXI HEALTH and Eaglepoint AI will not only enhance digital marketing ROI for domestic healthcare enterprises but also provide health data pipelines for AI models, contributing to the competitive and cooperative landscape across the "Data + Algorithm + Traffic" dimensions.

About Haoxi Health Technology Limited

Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Investor Relations

ir@haoximedia.com

HAO.................................https://stockcharts.com/h-sc/ui?s=HAO&p=W&b=5&g=0&id=p86431144783

HAO...........https://stockcharts.com/h-sc/ui?s=HAO&p=W&b=5&g=0&id=p86431144783

DILITION HITTING THEN RS

Post from another board, "$HAO based on the CEO ownership, that leaves the float at around 6m, food for thought. Could be tomorrow's banger.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175305571

HAO should trade at least 1-2$
Revenue: Approximately $48.52 million for FY24, reflecting a 72% increase compared to $28.23 million in the fiscal year ended June 30, 2023 ("FY23").
Gross Profit: Approximately $2.75 million for FY24, reflecting a 33.4% increase from $2.06 million in FY23.
Net Income: Approximately $1.29 million for FY24, reflecting a 33.2% increase from $0.97 million in FY23.
Total Assets: As of June 30, 2024, the Company's total assets increased to approximately $15.51 million, from $4.46 million at the end of FY23,
Post from another board.

$HAO Haoxi Health Technology sees FY24 revenue $48.52M vs. $28.23M last year

HAO projects revenue growth during FY24, which it attributes to the Company's strategic development in online advertising solutions, particularly through short video formats and news feed ads. The Company's proprietary data analysis software, Bidding Compass, enables it to optimize ad placements, which it believes has driven growth in both revenue and profit for FY24. Gross Profit: Approximately $2.75 million for FY24, reflecting a 33.4% increase from $2.06 million in FY23. Net Income: Approximately $1.29 million for FY24, reflecting a 33.2% increase from $0.97 million in FY23.

Total Assets: As of June 30, 2024, the Company's total assets increased to approximately $15.51 million, from $4.46 million at the end of FY23, reflecting HAO's operational scale and capital utilization after its initial public offering. "We believe that our preliminary FY24 results reflect the strength of our business model and our team's ability to navigate through a rapidly evolving online advertising landscape," said Mr. Zhen Fan, CEO of the Company. "Our dedicated team, coupled with our focus on the healthcare sector, has enabled us to consistently deliver value to our clients. We look forward to maintaining this momentum as we continue to expand our partnerships and enhance our service offerings."

CHING CHANG CHONG DUMPING

Nice action here

Woooo $4.61 now 😏

In at $4.21 for a fast scalp

HAO CHART